Predictive Oncology’s (NASDAQ: POAI) Subsidiary Refining, Strengthening Personalized Oncology Approach to Ovarian Cancer

April 19, 2021 12:15 PM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
  • Ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of female reproductive system
  • TumorGenesis can provide pharmaceutical companies newfound ability for more effective, expeditious drug development
  • Company is global developer of world-class, innovative technologies using 3D cell culture, media

In the treatment of cancer, most patients receive standard one-size-fits-all drug treatments identified from studying the cancers, treatments and results of other patients. In the evolving world of personalized oncology, the approach entails testing a variety of potential drugs on a patient’s unique tumor to discover which drug, or combination of drugs, might work best. That is precisely the approach that Predictive Oncology (NASDAQ: POAI), through its subsidiary TumorGenesis, takes in addressing ovarian cancer.

According to the American Cancer Society, ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system ( The ACS estimated that in&

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Investor Brand Network, Press Releases